Role of the insulin-like growth factor 1 (IGF1)/phosphoinositide-3-kinase (PI3K) pathway mediating physiological cardiac hypertrophy

Novartis Foundation Symposium

Volumn 274, Issue , 2006, Pages 90-111

  McMullen, Julie R ^a   Izumo, Seigo ^b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; S6 KINASE; SOMATOMEDIN C;

ANIMAL; BIOLOGICAL MODEL; CARDIOMEGALY; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CARDIOMEGALY; GENE EXPRESSION REGULATION; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SIGNAL TRANSDUCTION;

EID: 39049178436     PISSN: 15282511     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (85)

1. Akhter SA, Luttrell LM, Rockman HA, Iaccarino G, Lefkowitz RJ, Koch WJ 1998 Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 280:574-577
2. Antos CL, McKinsey TA, Frey N et al 2002 Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 99:907-912
3. Aoki H, Izumo S 2001 Signal transduction of cardiac myocyte hypertrophy. In: Sperelakis N, Kurachi Y, Terzic A, Cohen MV (eds) Heart physiology and pathology, 4th edn, Academic Press, San Diego, p 1065-1086
4. Bowman JC, Steinberg SF, Jiang T, Geenen DL, Fishman GI, Buttrick PM 1997 Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest 100:2189-2195
5. Braz JC, Bueno OF, Liang Q et al 2003 Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J Clin Invest 111:1475-1186
6. Bueno OF, De Windt LJ, Tymitz KM et al 2000 The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19:6341-6350
7. Bueno OF, Wilkins BJ, Tymitz KM et al 2002 Impaired cardiac hypertrophic response in Calcineurin Abeta-deficient mice. Proc Natl Acad Sci USA 99:4586-4591
8. Cardiogenomics. An NHLBI sponsored program for genomic applications. In: 2001-2003
9. Chan TO, Rittenhouse SE, Tsichlis PN 1999 AKT/PKB and other D3 phosphoinositideregulated kinases: kinase activation by phosphoinositide- dependent phosphorylation. Annu Rev Biochem 68:965-1014
10. Chien KR, Knowlton KU, Zhu H, Chien S 1991 Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. Faseb J 5:3037-3046
11. Chien KR, Zhu H, Knowlton KU et al 1993 Transcriptional regulation during cardiac growth and development. Annu Rev Physiol 55:77-95
12. Chou MM, Blenis J 1995 The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signalling. Curr Opin Cell Biol 7:806-814
13. Choukroun G, Hajjar R, Fry S et al 1999 Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases. J Clin Invest 104:391-398
14. Cohn JN, Bristow MR, Chien KR et al 1997 Report of the national heart, lung, and blood institute special emphasis panel on heart failure research. Circulation 95:766-770
15. Condorelli G, Drusco A, Stassi G et al 2002 Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA 99:12333-12338
16. Cook SA, Sugden PH, Clerk A 1999 Activation of c-Jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischaemic heart disease. J Mol Cell Cardiol 31:1429-1434
17. Cook SA, Matsui T, Li L, Rosenzweig A 2002 Transcriptional effects of chronic Akt activation in the heart. J Biol Chem 277:22528-22533
18. Cooper Gt 1987 Cardiocyte adaptation to chronically altered load. Annu Rev Physiol 49:501-518
19. D'Angelo DD, Sakata Y, Lorenz JN et al 1997 Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci USA 94:8121-8126
20. Delaughter MC, Taffet GE, Fiorotto ML, Entman ML, Schwartz RJ 1999 Local insulin-like growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice. Faseb J 13:1923-1929
21. Devereux RB 2000 Therapeutic options in minimizing left ventricular hypertrophy. Am Heart J 139(1 Pt 2):S9-14
22. Dorn GW 2nd, Robbins J, Sugden PH 2003 Phenotyping hypertrophy: eschew obfuscation. Circ Res 92:1171-1175
23. Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, Ross J Jr 1995 Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 95:619-627
24. Fagard RH 1997 Impact of different sports and training on cardiac structure and function. Cardiol Clin 15:397-412
25. Ferrans VJ 1984 Cardiac hypertrophy: Morphological aspects. In: Zak R (ed) Growth of the heart in health and disease. Raven Press, New York, p 187-239
26. Fiorotto ML, Schwartz RJ, Delaughter MC 2003 Persistent IGF-I overexpression in skeletal muscle transiently enhances DNA accretion and growth. Faseb J 17:59-60
27. Froelicher VF, Myers JN 2000 In: Froelicher VF, Myers JN (eds) Exercise and the heart. W.B. Saunders Company, Philadelphia
28. Geenen DL, Malhotra A, Buttrick PM 1996 Angiotensin receptor 1 blockade does not prevent physiological cardiac hypertrophy in the adult rat. J Appl Physiol 81:816-821
29. Hahn HS, Marreez Y, Odley A et al 2003 Protein kinase Calpha negatively regulates systolic and diastolic function in pathological hypertrophy. Circ Res 93:1111-1119
30. Hildick-Smith DJ, Shapiro LM 2001 Echocardiographic differentiation of pathological and physiological left ventricular hypertrophy. Heart 85:615-619
31. Holtwick R, van Eickels M, Skryabin BV et al 2003 Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 111:1399-1407
32. Horio T, Nishikimi T, Yoshihara F, Matsuo H, Takishita S, Kangawa K 2000 Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension 35(1 Pt 1):19-24
33. Hudlicka O, Brown MD 1996 Postnatal growth of the heart and its blood vessels. J Vasc Res 33:266-287
34. Hunter JJ, Chien KR 1999 Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 341:1276-1283
35. Iemitsu M, Miyauchi T, Maeda S et al 2001 Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat. Am J Physiol Regul Integr Comp Physiol 281:R2029-2036
36. Inagaki K, Hahn HS, Dorn GW 2nd, Mochly-Rosen D 2003 Additive protection of the ischemic heart ex vivo by combined treatment with delta-protein kinase C inhibitor and epsilon-protein kinase C activator. Circulation 108:869-875
37. Izumo S, Nadal-Ginard B, Mahdavi V 1988 Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci USA 85:339-343
38. Kaplan ML, Cheslow Y, Vikstrom K et al 1994 Cardiac adaptations to chronic exercise in mice. Am J Physiol 267(3 Pt 2):H1167-1173
39. Kishimoto I, Rossi K, Garbers DL 2001 A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc Natl Acad Sci USA 98:2703-2706
40. Kodama Y, Umemura Y, Nagasawa S et al 2000 Exercise and mechanical loading increase periosteal bone formation and whole bone strength in C57BL/6J mice but not in C3H/Hej mice. Calcif Tissue Int 66:298-306
41. Koziris LP, Hickson RC, Chatterton RT Jr et al 1999 Serum levels of total and free IGF-I and IGFBP-3 are increased and maintained in long-term training. J Appl Physiol 86:1436-1442
42. Lembo G, Rockman HA, Hunter JJ et al 1996 Elevated blood pressure and enhanced myocardial contractility in mice with severe IGF-1 deficiency. J Clin Invest 98:2648-2655
43. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP 1990 Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322:1561-1566
44. Liang Q, Molkentin JD 2003 Redefining the roles of p38 and JNK signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models. J Mol Cell Cardiol 35:1385-1394
45. Liang Q, Bueno OF, Wilkins BJ, Kuan CY, Xia Y, Molkentin JD 2003 c-Jun N-terminal kinases ( JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling. EMBO J 22:5079-5089
46. Luo J, McMullen JR, Sobkiw CL et al 2005 Class IA Phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol Cell Biol 25:9491-9502
47. MacLellan WR, Schneider MD 2000 Genetic dissection of cardiac growth control pathways. Annu Rev Physiol 62:289-319
48. Matsui T, Li L, Wu JC et al 2002 Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem 277:22896-22901
49. McMullen JR, Shioi T, Zhang L et al 2003 Phosphoinositide 3-kinase(p110?) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA 100:12355-12360
50. McMullen JR, Shioi T, Huang WY et al 2004a The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110?) pathway. J Biol Chem 279:4782-4793
51. McMullen JR, Sherwood MC, Tarnavski O et al 2004b Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 109:3050-3055
52. McMullen JR, Shioi T, Zhang L et al 2004c Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. Mol Cell Biol 24:6231-6240
53. Minamino T, Yujiri T, Terada N et al 2002 MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq. Proc Natl Acad Sci USA 99:3866-3871
54. Molkentin JD 2003 A friend within the heart: natriuretic peptide receptor signaling. J Clin Invest 111:1275-1277
55. Molkentin JD, Lu JR, Antos CL et al 1998 A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93:215-228
56. Neri Serneri GG, Boddi M, Modesti PA et al 2001a Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes. Circ Res 89:977-982
57. Neri Serneri GG, Boddi M, Poggesi L et al 2001b Activation of cardiac renin-angiotensin system in unstable angina. J Am Coll Cardiol 38:49-55
58. Olson EN, Williams RS 2000 Calcineurin signaling and muscle remodeling. Cell 101:689-692
59. Orenstein TL, Parker TG, Butany JW et al 1995 Favorable left ventricular remodeling following large myocardial infarction by exercise training. Effect on ventricular morphology and gene expression. J Clin Invest 96:858-866
60. Reiss K, Cheng W, Ferber A et al 1996a Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice. Proc Natl Acad Sci USA 93:8630-8635
61. Reiss N, Oplatka A, Hermon J, Naor Z 1996b Phosphatidylserine directs differential phosphorylation of actin and glyceraldehyde-3-phosphate dehydrogenase by protein kinase C: possible implications for regulation of actin polymerization. Biochem Mol Biol Int 40:1191-1200
62. Richey PA, Brown SP 1998 Pathological versus physiological left ventricular hypertrophy: a review. J Sports Sci 16:129-141
63. Roman BB, Geenen DL, Leitges M, Buttrick PM 2001 PKC-beta is not necessary for cardiac hypertrophy. Am J Physiol Heart Circ Physiol 280:H2264-2270
64. Rothermel BA, McKinsey TA, Vega RB et al 2001 Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 98:3328-3333
65. Sadoshima J, Montagne O, Wang Q et al 2002 The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. J Clin Invest 110:271-279
66. Schaible TF, Scheuer J 1984 Response of the heart to exercise training. In: Zak R (ed) Growth of the heart in health and disease. Raven Press, New York
67. Schaible TF, Malhotra A, Ciambrone GJ, Scheuer J 1986 Chronic swimming reverses cardiac dysfunction and myosin abnormalities in hypertensive rats. J Appl Physiol 60:1435-1441
68. Scheuer J, Malhotra A, Hirsch C, Capasso J, Schaible TF 1982 Physiologic cardiac hypertrophy corrects contractile protein abnormalities associated with pathologic hypertrophy in rats. J Clin Invest 70:1300-1305
69. Shioi T, Kang PM, Douglas PS et al 2000 The conserved phosphoinositide 3-kinase pathway determines heart size in mice. Embo J 19:2537-2548
70. Shioi T, McMullen JR, Kang PM et al 2002 Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 22:2799-2809
71. Shioi T, McMullen JR, Tarnavski O et al 2003 Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 107:1664-1670
72. Shiraishi I, Melendez J, Ahn Y et al 2004 Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes. Circ Res 884-891
73. Sugden PH, Clerk 1998 A cellular mechanisms of cardiac hypertrophy. J Mol Med 76:725-746
74. Takeishi Y, Ping P, Bolli R, Kirkpatrick DL, Hoit BD, Walsh RA 2000 Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy. Circ Res 86:1218-1223
75. Tanaka N, Ryoke T, Hongo M et al 1998 Effects of growth hormone and IGF-I on cardiac hypertrophy and gene expression in mice. Am J Physiol 275(2 Pt 2):H393-399
76. Tarnavski O, McMullen JR, Schinke M, Nie Q, Kong S, Izumo S 2004 Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies. Physiol Genomics 16:349-360
77. Thomas G, Hall MN 1997 TOR signalling and control of cell growth. Curr Opin Cell Biol 9:782-787
78. Toker A, Cantley LC 1997 Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 387:673-676
79. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD 1997 Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 22:267-272
80. Wakasaki H, Koya D, Schoen FJ et al 1997 Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci USA 94:9320-9325
81. Weber KT, Brilla CG 1991 Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83:1849-1865
82. Weber KT, Brilla CG, Janicki JS 1993 Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 27:341-348
83. Wettschureck N, Rutten H, Zywietz A et al 2001 Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. Nat Med 7:1236-1240
84. Wilkins BJ, Dai YS, Bueno OF et al 2004 Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 94:110-118
85. Yeh JK, Aloia JF, Chen M, Ling N, Koo HC, Millard WJ 1994 Effect of growth hormone administration and treadmill exercise on serum and skeletal IGF-I in rats. Am J Physiol 266(1 Pt 1):E129-135